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Abstract Cartilage is an avascular tissue, and exhibits anti-
angiogenic properties. Cartilage extracts have been shown to 
contain an inhibitor for DNA synthesis in vascular endothelial 
cells in vitro. Here we purified the inhibitory activity in the 10-50 
kDa fraction of guanidine extracts from fetal bovine epiphyseal 
cartilage, and found that the inhibitor was identical with 
chondromodulin-I (ChM-I). Purified ChM-I inhibited tube 
morphogenesis of cultured vascular endothelial cells, as well as 
DNA synthesis. These results indicate that cartilage-specific 
glycoprotein ChM-I may participate in the maintenance of 
avascularity and anti-angiogenic properties of cartilage. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Angiogenic molecules such as fibroblast growth factor-2 
(FGF-2) [1], transforming growth factor-ß (TGF-ß) [2] and 
vascular endothelial growth factor (VEGF) [3] are reported 
to be present in cartilage. Contrary to these observations, 
cartilage is known to be uniquely avascular among the mes-
enchymal tissues and exhibits resistance to vascular invasion. 
The resistance of cartilage to vascular invasion was first 
studied by Kuettner and his coworkers [4]. They demonstrated 
that a specific elastase inhibitor can be a potential anti-vascu-
lar invasion factor [5]. Since vascular invasion involves local 
degradation of the basement membrane surrounding the en-
dothelium, the process can be inhibited by inhibition of pro-
teinases [6,7]. Moses and others identified tissue inhibitors of 
metalloproteinase (TIMP) and its related molecules as an an-
giogenesis inhibitor [8-10]. However, no cartilage-specific 
macromolecules capable of inhibiting growth of endothelial 
cells have been identified. 
We previously identified a growth promoting factor chon-
dromodulin-I (ChM-I) in cartilage which stimulated D N A 
synthesis and proteoglycan synthesis in the cultured growth 
plate chondrocytes [11]. Chondromodulin-I is a 25 k D a gly-
coprotein with 121 amino acid residues, and encoded as a C-
terminal port ion of a larger precursor (335 amino acids) [11]. 
Mature ChM-I is assumed to be secreted from chondrocytes 
after proteolytic cleavage by a precursor-endoprotease, furin 
[12]. During purification, we found that an endothelial cell 
growth inhibitory activity was closely associated with C h M -
I. In the present study, we demonstrated that ChM-I inhibits 
D N A synthesis and tube morphogenesis of cultured vascular 
endothelial cells. The inhibitory actions of ChM-I were com-
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pared to those of the known endothelial growth inhibitors, 
platelet factor-4 (PF4) and fumagillin derivatives. 
2. Materials and methods 
2.1. Materials 
Fumagillin and human PF4, fatty acid-free bovine serum albumin 
were purchased from Sigma Chemicals (St. Louis, MO). Synthetic 
AGM1470 and synthetic PF4(58-70) were obtained from Mitsubishi 
Chemical (Tokyo, Japan). 
2.2. Purification 
Purification of ChM-I was carried out, as previously described [11]. 
In brief, fetal bovine epiphyseal cartilage (2 kg) was homogenized and 
extracted with 1 M guanidinium chloride, and then fractionated with 
45-60% acetone. The precipitates were subfractionated by successive 
ultrafiltration into the 10-50 kDa fraction in 4 M guanidinium chlo-
ride containing 1 M NaCl and 20 mM Tris-HCl (pH 7.4). The 10-50 
kDa fraction (109 mg) was applied to a Sephacryl S-200 column 
(3.0X90 cm) equilibrated with the same buffer, and the eluate was 
collected in 8 ml fractions. Bioactive fractions were pooled, and dia-
lyzed. The dialyzed material (13 mg) was applied to a heparin Toyo-
pearl affinity column (0.7x20 cm) equilibrated with 20 mM sodium 
phosphate (pH 7.4) containing 0.15 M NaCl and 0.03% CHAPS, and 
then eluted with a linear gradient of 0.15-1.2 M NaCl (2 mg). Finally, 
ChM-I was purified to homogeneity by HPLC on a reverse-phase 
column of YMC C4 (0.46x15 cm) equilibrated with 25% acetoni-
trile/2-propanol (3/7, v/v) in 0.1% trifluoroacetic acid. The column 
was developed with a linear gradient of 25-70% of the same solvent. 
About 60 ug of ChM-I was isolated. The sequence data of ChM-I is 
available from GenBank under accession number M65081. 
2.3. Cell culture and thymidine incorporation 
Bovine carotid artery endothelial (BCAE) cells were isolated from 
adult bovine carotid arteries and cultured as reported [13,14]. In brief, 
carotid arteries were opened lengthwise. The endothelial cell layer was 
obtained by gently scraping the intimai surface with a scalpel. The 
cells were cultured in RPMI1640 medium containing 10% fetal bovine 
serum (FBS) at 37°C under 5% CO2 in air. After primary culture, the 
cells were subcultured for making a stock of frozen cells. Cells at 
passages 10-20 were used. For determination of DNA synthesis in 
the cells, BCAE cells (4x 103 cells/well) were inoculated onto 96-mul-
tiwell plated (Corning) and cultured in 0.1 ml of MEM containing 
10% FBS. When the culture became subconfluent approximately two 
days before the cells stop growing at confluency, the medium was 
replaced by MEM containing 10% FBS and a test sample. The cells 
were incubated for 16 h and labeled with [3H]thymidine (5 uCi/ml, 
NEN) for the last 4 h. Radioactivity incorporated into DNA was 
determined with a scintillation spectrometer. 
2.4. Tube morphogenesis 
Experiment on tube morphogenesis of BCAE cells were carried out 
in duplicate by the method described previously [14]. A mixture of 
0.3% type I collagen solution (0.6 ml; Koken, Tokyo, Japan), 0.1 M 
NaOH (75 ul) and 10-fold concentrated MEM (75 ul) were poured 
into 12-multiwell plates and allowed to form a lower gel at 37°C. 
Then, 1 X 105 cells in 2 ml of MEM containing 10% FBS were inocu-
lated onto the gel and incubated for 24 h. Subsequently, the medium 
was aspirated and an aqueous solution (40 ul) containing a test sam-
ple was added. The mixed collagen solution (0.75 ml) was overlaid on 
the cells to form an upper layer. Lastly, MEM containing 10% FBS 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / / S 0 0 1 4 - 5 7 9 3 (9 7 ) 0 1 1 5 1 - 4 
322 Y. Hiraki et al.lFEBS Letters 415 (1997) 321-324 
was added on the collagen gel. On the third day of culture, morpho-
logical changes of the cells were observed under a phase-contrast 
microscope. In the absence of an inhibitor, 70-90% of the cells formed 
tube-like cellular networks. For semiquantitative analysis of tube mor-
phogenesis [15], cells forming tube-like cellular networks ( > 100 urn in 
length) were counted after viable staining of the cells with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) [16], 
By serial dilutions of test samples, we determined a dose range of a 
test sample to cause 50% inhibition of tube formation over the con-
trol. 
3. Results and discussion 
Previously we reported that the 100-300 kDa fraction of 
cartilage extracts contained an endothelial cell growth inhib-
itor [17]. The fractionated cartilage extracts inhibited growth 
of melanoma due to its anti-angiogenic action. Unlike other 
angiogenesis inhibitors [8-10], our preparation of cartilage 
extracts did not associate with the inhibitory activity on col-
lagenase. During purification of cartilage-specific growth pro-
moting factor ChM-I [11], we found that the 10-50 kDa frac-
tion also exhibited an inhibitory action on DNA synthesis in 
subconfluent BCAE cells growing in MEM containing 10% 
FBS. The concentration required for 50% inhibition (IC50) 
on DNA synthesis was about 30 ug/ml (Fig. 1). As shown 
in Fig. 2A, the DNA synthesis inhibitory activity was coeluted 
with materials having a molecular mass of 10-30 kDa. The 
active fractions (fractions 25 to 31) were pooled and dialyzed 
against 20 mM sodium phosphate (pH 7.4) containing 0.15 M 
NaCl. Then the materials were subjected to heparin Toyopearl 
affinity chromatography (Fig. 2B). Materials not bound to the 
column (Hep.-pass.) exhibited no inhibitory action on 
[3H]thymidine incorporation by BCAE cells in culture (Fig. 
1). The bound materials were eluted with a linear gradient 
from 0.15 to 1.2 M NaCl (Fig. 2B). Bioactivity was recovered 
in the fraction eluted with 0.5 M NaCl. The active fractions 
were pooled (Hep. 0.5-1.2 M). The IC50 of the Hep. 0.5-1.2 
M fraction was approximately 3 ug/ml (Fig. 1). 
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Fig. 1. Dose-response curves of purified ChM-I. Subconfluent 
BCAE cells were treated for 16 h with various concentrations of the 
10-50 kDa fraction (o), the Hep.-pass. fraction (•), the Hep. 0.5-
1.2 M fraction (■) and purified ChM-I (D). The [3H]thymidine in-
corporation into control wells treated with 0.1% BSA in phosphate-
buffered saline was 112682 ±6032 dpm/well (100 ±5%). Points repre-
sent means ± standard deviations in triplicate assays. 
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Fig. 2. Chromatographie separation of an DNA synthesis inhibitory 
activity in cartilage extracts. Subconfluent BCAE cells were incu-
bated with MEM containing 10% FBS and a test sample for 16 h, 
and labeled with [3H]thymidine for the last 4 h. Aliquots from each 
Chromatographie fraction were assayed. In A, elution profile of the 
10-50 kDa fraction on Sephacryl S-200 chromatography is shown. 
Bioactive fractions were pooled, and then separated by a heparin af-
finity column (B). The shaded bars represent the inhibitory activity 
on [3H]thymidine incorporation into BCAE cells in triplicate assays. 
The DNA synthesis inhibitory activity was finally purified 
to homogeneity by YMC C4 reverse-phase HPLC. Bioactivity 
was recovered only in the fraction corresponding to ChM-I. 
SDS-PAGE of the active fraction gave a single diffuse band of 
25 kDa (data not shown). Purified ChM-I inhibited DNA 
synthesis in BCAE cells in a dose-dependent manner (Fig. 
1). The IC5o of ChM-I was approximately 200 ng/ml. 
Angiogenesis is a complex process which includes local deg-
radation of the basement membrane, migration and prolifer-
ation of endothelial cells, and formation of new capillaries 
[18]. In this study, we examined the effect of ChM-I on tube 
morphogenesis in vitro by monitoring cell-shape changes of 
BCAE cells cultured in collagen gel [14,19]. We plated BCAE 
cells onto type I collagen gel and covered them with an upper 
layer of collagen gel. In the presence of 10% FBS, the cells 
elongated and reorganized into a network of capillary-like 
structures within three days (Fig. 3). In contrast, tube mor-
phogenesis was markedly inhibited by 1 ug/ml purified ChM-I 
(Fig. 3). The Hep. 0.5-1.2 M fraction (10 ug/ml) similarly 
inhibited tube morphogenesis (data not shown). These results 
suggest that ChM-I also affects the last step of angiogenesis, 
tube morphogenesis, as well as growth of endothelial cells. 
Platelet factor-4 (PF4) is a prototype of endogenous angio-
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Fig. 3. Effect of ChM-I on tube morphogenesis of BCAE cells in a collagen gel. BCAE cells were inoculated onto a collagen gel in 12-multiwell 
plates in the presence of 0.1% BSA alone (A), 0.1 ug/well purified ChM-I (B), 1 ug/well purified ChM-I (C), 0.01 ug/well PF4 (D), or 0.1 ug/ 
well PF4 (E). Bar represents 200 |xm. 
genesis inhibitors [20,21]. The C-terminal 13 amino acids of 
PF4(58-70) have been suggested to participate in the inhibi-
tory activity of PF4 [22]. The fumagillin derivative AGM1470 
(or otherwise called TNP-470) was also shown to inhibit 
growth of cultured endothelial cells and tumor induced angio-
genesis [23,24]. In this study, ChM-I was compared to PF4 
and AGM1470 in terms of their inhibitory activities on DNA 
synthesis and tube morphogenesis of BCAE cells in vitro. The 
results were evaluated as the concentrations required for 50% 
inhibition of [3H]thymidine incorporation and tube morpho-
genesis of the cells in the presence of 10% FBS (Table 1). 
Tube morphogenesis was semiquantitatively assessed by 
counting cells forming tube-like cellular networks after stain-
ing of the viable cells with MTT [16,25]. Fumagillin and 
AGM1470 inhibited DNA synthesis at concentrations of 
5 pmol/ml and 0.5 pmol/ml, respectively. These were about 
100-fold lower than those required for inhibition of tube mor-
phogenesis. On the other hand, PF4 inhibited formation of 
tube-like cellular networks as characterized by its IC50 (1.2-12 
pmol/well; Fig. 3), whereas a much higher dose was required 
for inhibition of DNA synthesis. Similarly PF4(58-70) inhib-
ited formation of cellular networks, but it was almost inactive 
Table 1 
Effects of various inhibitors on DNA synthesis and tube morphogenesis 
Addition Inhibition of DNA synthesis (IC50)
a Inhibition of tube morphogenesis (IC5o)
b 
Fumagillin 
AGM1470 (TNP-470) 
PF4(58-70) 
PF4 
ChM-I 
5 pmol/ml 
0.25-0.5 pmol/ml 
> 11000 pmol/ml 
>2000 pmol/ml 
8-23 pmol/ml 
> 2500 pmol/well 
25-250 pmol/well 
> 770 pmol/well 
1.2-12 pmol/well 
11-38 pmol/well 
aThe relative potencies of various inhibitors were compared in terms of their concentrations required for the 50% inhibition of [3H]thymidine 
incorporation (IC50) into BCAE cells cultured in the presence of 10% FBS, determined from the dose-response profiles. Two independent experi-
ments were performed. 
bBCAE cells were cultured on a collagen gel containing 10% FBS in the presence or absence of the inhibitory agents for three days. Cells forming 
tube-like cellular networks (> 100 |xm in length) were counted. The relative potencies of the agents were compared in terms of their concentrations 
required for the 50% inhibition of tube formation stimulated by 10% FBS (IC50). Two independent experiments were performed. 
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on D N A synthesis of the cells. Thus, AGM1470 inhibits an-
giogenesis due to its inhibitory action on growth of endothe-
lial cells, whereas PF4 acts on tube morphogenesis. In con-
trast, ChM-I inhibited both D N A synthesis and tube 
morphogenesis at a similar dose (Table 1). 
ChM-I was first discovered as a functional matrix compo-
nent in cartilage which stimulates growth and phenotypic ex-
pression of chondrocytes [11]. The ChM-I transcripts were 
specifically expressed in cartilage. Recently, we demonstrated 
by using a chondrogenic cell line A T D C 5 that ChM-I tran-
scripts are expressed in chondrocytes in a differentiation-de-
pendent manner [26]. Although ChM-I stimulated growth of 
osteoblasts as well as chondrocytes, it exerted no growth stim-
ulation in cultured fibroblasts [26]. Members of thrombospon-
din (TSP) family are other extracellular matrix components 
with anti-angiogenic properties [27,28]. These molecules are 
also found in cartilage, but have a broader distribution in 
the body [29-31]. It is not clear at present whether these 
molecules also function as cartilage-derived anti-angiogenic 
factor. Recently we described isolation of chondromodulin-
II (ChM-II) which stimulates growth of osteoblasts, but has 
no structural similarity to ChM-I [32]. ChM-I I did not affect 
growth of cultured vascular endothelial cells (data not shown). 
These results indicate a possibility that ChM-I may confer 
anti-angiogenic properties on cartilage as a cartilage-specific 
matrix component. The in vivo studies of ChM-I to show an 
anti-angiogenic action in vivo are now underway. 
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